FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162225583> ?p ?o ?g. }

• W2162225583 endingPage "522" @default.
• W2162225583 startingPage "515" @default.
• W2162225583 abstract "Abstract Purpose: The primary objective of this phase I study was to determine the maximum tolerated dose for pemetrexed, alone and in combination with carboplatin, with concurrent radiotherapy. Experimental Design: Patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) or esophageal cancer were treated every 21 days for two cycles. Regimen 1 was pemetrexed (200-600 mg/m2); regimen 2 was pemetrexed (500 mg/m2) with escalating carboplatin doses (AUC = 4-6). Both regimens included concurrent radiation (40-66 Gy; palliative-intent doses were lower). Results: Thirty patients (18 locally advanced and 12 metastatic with dominant local symptoms) were enrolled, with an Eastern Cooperative Oncology Group performance status of 0/1/2 (n = 8/21/1). All dose levels were tolerable for regimen 1 (n = 18: 15 NSCLC and 3 esophageal cancers) and regimen 2 (n = 12: all NSCLC). In regimen 1, one dose-limiting toxicity (grade 4 esophagitis/anorexia) occurred (500 mg/m2). Grade 3 neutropenia (3 of 18 patients) was the main hematologic toxicity. In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m2; AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity. Four complete responses (2 pathology proven) and eight partial responses were observed. When systemically active chemotherapy doses were reached, further dose escalation was discontinued, and a phase II dose-range was established (pemetrexed 500 mg/m2 and carboplatin AUC = 5-6). Conclusions: The combination of pemetrexed (500 mg/m2) and carboplatin (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity. To further determine efficacy, safety profile, and optimal dosing, the Cancer and Leukemia Group B study 30407 is currently evaluating this regimen in patients with unresectable stage III NSCLC." @default.
• W2162225583 created "2016-06-24" @default.
• W2162225583 creator A5001479339 @default.
• W2162225583 creator A5003826371 @default.
• W2162225583 creator A5007393455 @default.
• W2162225583 creator A5008467612 @default.
• W2162225583 creator A5012655110 @default.
• W2162225583 creator A5026127184 @default.
• W2162225583 creator A5038481817 @default.
• W2162225583 creator A5045444974 @default.
• W2162225583 creator A5063904421 @default.
• W2162225583 creator A5063976463 @default.
• W2162225583 creator A5073338061 @default.
• W2162225583 date "2007-01-15" @default.
• W2162225583 modified "2023-10-11" @default.
• W2162225583 title "A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer" @default.
• W2162225583 cites W1550111394 @default.
• W2162225583 cites W1837121308 @default.
• W2162225583 cites W1848316250 @default.
• W2162225583 cites W1874925441 @default.
• W2162225583 cites W1910732341 @default.
• W2162225583 cites W1944220675 @default.
• W2162225583 cites W1970641297 @default.
• W2162225583 cites W1974204289 @default.
• W2162225583 cites W1975081329 @default.
• W2162225583 cites W1976565907 @default.
• W2162225583 cites W1984357146 @default.
• W2162225583 cites W1985385147 @default.
• W2162225583 cites W1988338874 @default.
• W2162225583 cites W1990353764 @default.
• W2162225583 cites W1993312546 @default.
• W2162225583 cites W1995634658 @default.
• W2162225583 cites W1996141967 @default.
• W2162225583 cites W2019672478 @default.
• W2162225583 cites W2037139573 @default.
• W2162225583 cites W2051767374 @default.
• W2162225583 cites W2102627969 @default.
• W2162225583 cites W2104805235 @default.
• W2162225583 cites W2105024669 @default.
• W2162225583 cites W2110730246 @default.
• W2162225583 cites W2114998251 @default.
• W2162225583 cites W2115658330 @default.
• W2162225583 cites W2115724188 @default.
• W2162225583 cites W2120742888 @default.
• W2162225583 cites W2129622436 @default.
• W2162225583 cites W2134667653 @default.
• W2162225583 cites W2135009190 @default.
• W2162225583 cites W2136503777 @default.
• W2162225583 cites W2136887681 @default.
• W2162225583 cites W2138837920 @default.
• W2162225583 cites W2142703207 @default.
• W2162225583 cites W2145653040 @default.
• W2162225583 cites W2150279374 @default.
• W2162225583 cites W2160131381 @default.
• W2162225583 cites W2338638341 @default.
• W2162225583 cites W4239533623 @default.
• W2162225583 cites W4317564151 @default.
• W2162225583 doi "https://doi.org/10.1158/1078-0432.ccr-06-1058" @default.
• W2162225583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17255273" @default.
• W2162225583 hasPublicationYear "2007" @default.
• W2162225583 type Work @default.
• W2162225583 sameAs 2162225583 @default.
• W2162225583 citedByCount "82" @default.
• W2162225583 countsByYear W21622255832012 @default.
• W2162225583 countsByYear W21622255832013 @default.
• W2162225583 countsByYear W21622255832014 @default.
• W2162225583 countsByYear W21622255832015 @default.
• W2162225583 countsByYear W21622255832016 @default.
• W2162225583 countsByYear W21622255832017 @default.
• W2162225583 countsByYear W21622255832018 @default.
• W2162225583 countsByYear W21622255832019 @default.
• W2162225583 countsByYear W21622255832020 @default.
• W2162225583 crossrefType "journal-article" @default.
• W2162225583 hasAuthorship W2162225583A5001479339 @default.
• W2162225583 hasAuthorship W2162225583A5003826371 @default.
• W2162225583 hasAuthorship W2162225583A5007393455 @default.
• W2162225583 hasAuthorship W2162225583A5008467612 @default.
• W2162225583 hasAuthorship W2162225583A5012655110 @default.
• W2162225583 hasAuthorship W2162225583A5026127184 @default.
• W2162225583 hasAuthorship W2162225583A5038481817 @default.
• W2162225583 hasAuthorship W2162225583A5045444974 @default.
• W2162225583 hasAuthorship W2162225583A5063904421 @default.
• W2162225583 hasAuthorship W2162225583A5063976463 @default.
• W2162225583 hasAuthorship W2162225583A5073338061 @default.
• W2162225583 hasBestOaLocation W21622255831 @default.
• W2162225583 hasConcept C126322002 @default.
• W2162225583 hasConcept C143998085 @default.
• W2162225583 hasConcept C2776256026 @default.
• W2162225583 hasConcept C2776694085 @default.
• W2162225583 hasConcept C2777063308 @default.
• W2162225583 hasConcept C2777240266 @default.
• W2162225583 hasConcept C2778239845 @default.
• W2162225583 hasConcept C2779134260 @default.
• W2162225583 hasConcept C2779920096 @default.
• W2162225583 hasConcept C2780873365 @default.
• W2162225583 hasConcept C2781413609 @default.
• W2162225583 hasConcept C2781451048 @default.
• W2162225583 hasConcept C29730261 @default.

• next